FDA and ADHD Stimulant Medication. Science or Stigma? Part 2
See Also Part 1 Federal health advisers said Wednesday that Ritalin and other drugs for attention deficit hyperactivity disorder should not carry strong ”black-box” warnings about potential cardiovascular and psychiatric risks. Rather, the Food and Drug Administration pediatric advisory committee recommended that the drug labels include warning language written so people can understand it. Looks […]
FDA and ADHD Stimulant Medication. Science or Stigma? Part 2 Read More »